Xconomy | Life Sciences - Business + Technology in the Exponential Economy

News Xpress

MORE NEWS XPRESS BRIEFS More

More

Boston
Biotech, Drugs, Multiple Sclerosis

Biogen Idec Accused Again of Excessive CEO Pay, Lousy Performance, By Big Shareholder

Luke Timmerman 11/20/09

[Update: 1:55 pm Eastern, 11/20/09] After a bitter standoff earlier this year with billionaire investor Carl Icahn over alleged mismanagement, Cambridge, MA-based Biogen Idec now faces another sharp attack from a major shareholder.

New York-based HealthCor Management, a hedge fund that invests in health and biotech companies, said today in a regulatory filing that Biogen (NASDAQ: BIIB) overpays CEO James Mullen, that his performance has been poor, and that the company has a record of “excessive and... Read more »

Comments | Reprints | Share:

Email

Boston
deals, VC, mergers and acquisitions

Metcalfe Reflects on $2.7B 3Com Buyout, MyPunchbowl Parent Adds New Punch, $30M More for Fate Therapeutics, & More Boston Deals News

Ryan McBride 11/20/09

Dealmakers appear to be getting their business done before the week of Thanksgiving—because we’ve seen a decent stream of deal closings involving Boston-area life sciences and tech companies over the past week or so.

—Framingham, MA-based... Read more »

Comments | Reprints | Share:

Email

ADVERTISEMENT

Seattle
deals, startups, Investments

Under the Radar Deals: 12 Northwest Financings You Haven’t Heard About

Gregory T. Huang 11/20/09

We hope to make this a regular feature in our Xconomy cities. It’s a look at small financings of private companies in tech, life sciences, and cleantech. These are deals in the roughly $100,000 to $1... Read more »

Comments | Reprints | Share:

Email

Seattle
Biotech, Knee Surgery, Drugs

Omeros Banks on First FDA Filing Next Year, Plans to “Unlock” Inaccessible Drug Targets

Luke Timmerman 11/19/09

Seattle-based Omeros expects to apply for FDA clearance to start selling its first product by the second half of next year, and it also hoping to strike at least one partnership over the next couple of... Read more »

Comments | Reprints | Share:

Email

Boston
Biotech, Multiple Sclerosis, Drugs

Tysabri, the MS Drug Haunted by Deadly Side Effect, Doesn’t Look So Deadly Anymore

Luke Timmerman 11/19/09

Few doctors knew much about a rare brain infection called PML back in 2005, when two patients on a hot new multiple sclerosis drug from Biogen Idec and Elan died from the side effect. The infection,... Read more »

Comments (12) | Reprints | Share:

Email

San Diego
Roundup, Life Sciences, funding

Isis Extends Timeline on Cholesterol-Lowering Drug, FDA Delays Review of Cadence Pain Reliever, Fate Therapeutics Raises $30 Million, & More San Diego Life Sciences News

Denise Gellene 11/19/09

Drug development programs got extended at two San Diego life sciences companies, while others had some good news on the fund-raising front. We wrap it all up for you here.

—Fate Therapeutics, a startup... Read more »

Comments | Reprints | Share:

Email

Seattle
Roundup, Biotech, people

The Icos Alumni Guide, Trubion CEO Resigns, OVP Leads $30M Fate Deal, & More Seattle-Area Life Sciences News

Luke Timmerman 11/19/09

Comments (1) | Reprints | Share:

Email

Boston
Life Sciences, Roundup, Drug Development

A Week of Woe for Genzyme, A CPR App for Your iPhone, A Better Treatment for Opioid Dependence, and More Boston-Area Life Sciences News

Wade Roush 11/19/09

Comments (1) | Reprints | Share:

Email

Boston
Biotech, Kidney Disease, Drugs

Genzyme Halts Development of New Kidney Drug; A “Very Significant” Bust, Analyst Says

Luke Timmerman 11/18/09

Comments | Reprints | Share:

Email

San Diego
Biotech, cleantech, Research Labs

Biotech Meets Cleantech: GenVault Aims to Deep Six the Laboratory Deep Freeze

Denise Gellene 11/18/09

Comments | Reprints | Share:

Email

Seattle
Biotech, Genetics, Instruments

NanoString Forges Closer Ties With Broad Institute to See What Genetic Tool Can Really Do

Luke Timmerman 11/18/09

Comments | Reprints | Share:

Email

Seattle
Biotech, people, acquisitions

The Icos Alumni: Where Are They Now?

Luke Timmerman 11/18/09

Comments (2) | Reprints | Share:

Email

More recent posts More

More

Xconomist Forum - Insight & Opinion

Seattle
Biotech, Global Health, people

Beyond Anecdotes: Measuring Global Health Impact in Washington State

Lisa Cohen 11/18/09

The threat of global infectious disease was already a significant humanitarian concern when Ken Stuart set up his independent research lab in 1976. Now known as Seattle Biomedical Research Institute, Stuart’s... Read more »

Comments (1) | Reprints | Share:

Email

Seattle
Biotech, people, Entrepreneurship

It Takes a Village to Raise an Entrepreneur: Cultivating the Emerging Seattle Talent Pool

Anthony Rodriguez 11/4/09

It can be argued that among talent, cash and technology, no factor is more critical to a start up than talent. The talent drives innovation, attracts the venture capital and makes... Read more »

Comments (4) | Reprints | Share:

Email

San Diego
Biotech, Hepatitis C, HIV

Combination Drugs Are The Future for Hepatitis C

Steve Worland 11/3/09

Combination therapy has been a central component of treatment for certain viral diseases for more than 15 years. The benefits of combination therapy can arise from activation of multiple host pathways,... Read more »

Comments | Reprints | Share:

Email

Boston
Entrepreneurship, Education, MIT

MIT Elevator Pitch Contest Takes Startup Salesmanship to New Level

Gary Hochman 11/2/09

How does $300,000 an hour sound? Walking away with $5,000 for his 60-second pitch, the winner of Thursday night’s MIT $100K Elevator Pitch Contest (EPC), Rouzbeh Shahsavari, seemed pretty excited about... Read more »

Comments | Reprints | Share:

Email

San Diego
Commentary, Biotech, innovation

Lilly, With New Focus on Innovation (But Not Necessarily Inclusiveness), Opens San Diego Center for Biotech R&D

Bruce V. Bigelow 10/30/09

“Ouch.” I’m sorry to say I didn’t write about the grand opening that drug giant Eli Lilly held in La Jolla yesterday for its new biotechnology center of excellence. I didn’t... Read more »

Comments | Reprints | Share:

Email

Seattle
Biotech, Life Sciences, innovation

Your 2 cents for Life Science Innovation Northwest 2010

Valerie Carricaburu 10/27/09

[Editor's note: This editorial was co-authored by Neile Grayson, who, along with Valerie, is a co-chair of the program committee for Life Sciences Innovation Northwest 2010.]

On March 16-17,... Read more »

Comments | Reprints | Share:

Email

San Diego
Biotech, healthcare, people

BIL and TED’s Excellent (But Little Known) Healthcare Adventure in San Diego

Mary Canady 10/19/09

Comments (5) | Reprints | Share:

Email

Boston
VC, Life Sciences, Boston

What Boston’s Life Sciences Community is Taking for Granted

Jens Eckstein 10/15/09

Comments (4) | Reprints | Share:

Email

Seattle
Politics, Software, Stimulus

The Stimulus, UW, and Washington State

Ed Lazowska 10/13/09

Comments | Reprints | Share:

Email

Seattle
Education, Politics, Software

It’s Time for Washington to Commit to a 21st Century Education System for the 21st Century Economy

Susannah Malarkey 10/9/09

Comments | Reprints | Share:

Email

National
VC, startups, investment

Venture Model Makeover & Diet Plan—Step Two

Paul Kedrosky 10/8/09

Comments (9) | Reprints | Share:

Email

Seattle
Biotech, Politics, people

DC Matters, But Biotech Can’t Neglect City Hall

David Miller 10/7/09

Comments | Reprints | Share:

Email

More Xconomist posts More

More

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009, Xconomy, Inc. XCONOMY is a registered service mark of Xconomy, Inc. All rights reserved.
Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.